Clinical Trials Logo

Filter by:
NCT ID: NCT04532541 Recruiting - Clinical trials for Systemic Lupus Erythematosus

Monogenic Lupus in Childhood Onset Systemic Lupus Erythematosus

Start date: November 25, 2020
Phase:
Study type: Observational

The purpose of this study is to unravel the proportion of monogenic lupus in children onset Systemic lupus erythematosus (SLE), and to find out the diagnostic strategy for early detection of monogenic lupus.

NCT ID: NCT04532281 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Start date: November 1, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.

NCT ID: NCT04532268 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

Start date: August 23, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma.

NCT ID: NCT04532229 Recruiting - Clinical trials for Diffuse Intrinsic Pontine Glioma

Nimotuzumab in Combined With Chemoradiotherapy to Treat the Newly Diagnosed Diffuse Intrinsic Pontine Glioma in Children

Start date: April 3, 2021
Phase: Phase 3
Study type: Interventional

This is a prospective, open-label, single arm, multicenter clinical study. The purpose of the study is to evaluate the clinical efficacy and safety of combination Nimotuzumab with concurrent radiochemotherapy in children with newly diagnosed diffuse intrinsic pontine glioma(DIPG).

NCT ID: NCT04532203 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Start date: November 1, 2020
Phase: Early Phase 1
Study type: Interventional

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

NCT ID: NCT04531475 Recruiting - Reflux Esophagitis Clinical Trials

Study to Evaluate the Safety and Efficacy of X842 in Patients With Reflux Esophagitis

Start date: January 22, 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to investigate the efficacy and dose-effect relationship of X842 capsules at different dosages in the treatment of reflux esophagitis for 4 weeks in comparison with lansoprazole enteric-coated capsules.

NCT ID: NCT04531384 Recruiting - Clinical trials for Amphetamine Addiction

Robot-Assisted Intelligent Rehabilitation Treatment for Methamphetamine Use Disorders.

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

The purpose of this research is to evaluate the efficacy and safety of Robot-assisted rehabilitation intelligent system as a virtual stand-alone treatment, delivered with minimal clinical monitoring compared with treatment as usual in methamphetamine (MA) use disorders.

NCT ID: NCT04531228 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE-HAIC Plus Lenvatinib for Patients With Unresectable HCC: an Open-label, Single-arm, Phase 2 Trial

Thalen
Start date: October 11, 2020
Phase: N/A
Study type: Interventional

Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease. However, due to multiple tumors or poor hepatic function reserve in cirrhosis, surgical treatment is suitable for early-stage and well reserved liver function patients. Therefore, in clinical practice, transarterial chemoembolization (TACE) is a preferential and standard treatment of unresectable HCC. TACE has been proved to provide outstanding efficacy for treating advanced stage HCC patients. However, TACE is associated with a high rate of treatment failure for advanced HCC patients. EACH trial opened the door to FOLFOX-based system chemotherapy for advanced HCC patients. Recently, investigators have showed that hepatic arterial infusion of FOLFOX-based chemotherapy (HAIC) was safe and efficient for advanced HCC patients. The combination of TACE with HAIC (TACE-HAIC) was proved to increase the local doses of chemotherapeutic agents in the liver, reduce the viability of HCC cells and increase the hepatectomy rate in our previous study. Levatinib is a new treatment and offers relative high overall response rate for advanced HCC, which was approved in China and Japan. However, whether the combination of TACE-HAIC and Lenvatinib would increse tumor control for unresectable patients is still unknown. Thus, this single arm, phase 2 study is designed to analyze the safety and efficacy TACE-HAIC plus Lenvatinib for patients with unresectalbe HCC.

NCT ID: NCT04530773 Recruiting - Clinical trials for Visual Health of Virtual Reality

Key Evaluation Techniques and Criteria of Visual Health in Virtual Reality

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

China's VR industry is booming, but it also faces many problems. At present, industry standards for key physical parameters of virtual reality are still being explored. More and more attention has been paid to the visual health and safety of VR. Based on ophthalmology-neurologic technology, this study screened VR ocular safety parameters, constructed VR evaluation model and provided visual health evaluation system and standards for VR technology.

NCT ID: NCT04530721 Recruiting - Arteriosclerosis Clinical Trials

Investigation of Multiple Ultrasound Techniques for the Assessment of Carotid Plaque Vulnerability

Start date: January 1, 2020
Phase:
Study type: Observational [Patient Registry]

Stroke is a common clinical disease with high disability and mortality, which seriously threatens human life and health.Carotid atherosclerotic plaque rupture is an important pathogenic basis of ischemic stroke, so judging the stability of plaque has important clinical significance in preventing ischemic stroke.Ultrasound, as a convenient, rapid, noninvasive, radiation-free auxiliary examination technology, is widely used in carotid plaque stability examination.At present, there are many methods to judge the stability of carotid plaque based on ultrasound, including two-dimensional ultrasound, contrast-enhanced ultrasound, ultrasound elastography and so on. However, the results of plaque stability judgment by various technologies deviate greatly, which is not conducive to the development of standardized diagnosis and treatment strategies by clinicians.Studies have shown that because the neovascular epidermal cells in atherosclerotic plaques are imperfect, they are easy to rupture after stress, and the ruptured neovasculature will lead to intraplaque hemorrhage, thus causing plaque shedding, and eventually obstructing the cerebrovascular cause stroke.Contrast-enhanced ultrasound can sensitively detect the distribution and course of blood vessels.The plaque's softness and hardness determine its stability, while the difference of lipids, fibers and calcium in the plaque determines its softness and hardness.Real-time ultrasound elastography can provide tissue mechanical parameters, express the soft and hard of tissue with strain value, and provide important reference information for judging plaque stability.At present, elastography technology is used to reflect the hardness of plaque, so as to further judge its stability.However, the elastography parameters are prone to deviations due to the influence of the selected section and the selected region of interest.It can be seen from the above that there is currently a multi-modality method to evaluate the stability of carotid plaque using ultrasound, but there is a lack of a unified and objective reference standard for plaque stability assessment.The purpose of this study is to explore the comprehensive utilization of these modalities under the premise of optimizing each ultrasound modality to provide a unified and objective criterion for judging the stability of carotid plaque.